Objective To compare the effects of atorvastatin 10 mg versus 40 mg in circulating angiogenic cell mobilisations and in restoring coronary flow reserve (CFR) during the 8-month follow-up in patients with a first acute myocardial infarction (AMI).
Design CFR was measured using an intracoronary Doppler wire in 102 patients with AMI at baseline and at 8 months. Changes in the absolute number of circulating angiogenic cells were measured at baseline, 1 day, 5 days and at 8 months. Stented patients were randomly assigned to either low-dose atorvastatin 10 mg (ATOR10, n=52) or moderate-dose atorvastatin 40 mg (ATOR40, n=50).
Setting University Hospital.
Results CFR increased significantly in both groups during the 8-month follow-up. The 8-month increases from baseline in CFR were significantly greater in the ATOR40 group than in the ATOR10 group (0.99±0.69 vs 0.55±0.47, p=0.017, respectively). The serial increases in the absolute number of CD34+ and CXCR4+ cells were significantly greater in the ATOR40 group, especially at 24 h after the procedure (two-way repeated-measures analysis of variance: p=0.046 and p=0.022, respectively). Decreases from baseline for interleukin 6 (−2.94±3.31 vs −1.52±2.82 pg/ml), tumour necrosis factor α (−1.31±2.96 vs −0.01±1.29 pg/ml), soluble intercellular adhesion molecule-1 (−71±95 vs 37±83 ng/ml) and soluble vascular cell adhesion molecule-1 (−51±364 vs 190±204 ng/ml) were significantly greater in the ATOR40 group.
Conclusions The recovery of microvascular integrity after acute ischaemic injury in the ATOR40 group was expedited by greater circulating angiogenic cell mobilisations such as CD34+ and CXCR4+ cells, together with greater decreases in inflammatory cytokines and low-density lipoprotein-cholesterol concentrations.
Registration number http://ClinicalTrials.gov number, NCT00536887.
- Myocardial infarction
- coronary flow reserve
- angiogenic cell
- coronary haemodynamics
Statistics from Altmetric.com
Funding This study was supported by a grant (SC-4220) from Stem Cell Research Centre of the 21st Century Frontier Research Programme funded by the Ministry of Education, Science and Technology, Korea and by the Korea University Research Grants (R0805461, R0803941), by the Korean Institute of Medicine and by the Korea University Research Grants (R0600701, R0706511, R0701521).
Competing interests None.
Patient consent Obtained.
Ethics approval This study was conducted with the approval of the Korea University Anam Hospital Institutional Review Board.
Provenance and peer review Not commissioned; externally peer reviewed.